Multiple myeloma trials in Portugal

In Portugal 13 Also abroad 703

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Braga, Lisbon, Porto
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 2Taking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Braga, Lisbon, Porto, Vila Nova de Gaia
Age
18 years and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Braga, Lisbon, Porto, Vila Real
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Braga, Lisbon, Porto
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Porto
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Braga, Lisbon, Porto
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
Braga, Coimbra, Lisbon, Porto, Vila Real
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 2Taking people
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Where
Braga, Lisbon, Porto, Vila Nova de Gaia
Age
18 years and over
People
123 worldwide
Run by
Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Braga, Coimbra, Lisbon, Vila Nova de Gaia
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 3Not yet taking people in Portugal
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Braga, Lisbon, Porto, Vila Nova de Gaia
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Braga, Lisbon, Porto
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Coimbra, Porto
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
No phaseTaking people
European Myeloma Network (EMN) Sample Project
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
6,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06237803